Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daniel F. Leach"'
Autor:
Jayden Gracie, E. Charles Fortune, Christopher G. Morris, Daniel F. Leach, William M. Mendenhall
Publikováno v:
American Journal of Clinical Oncology. 46:167-171
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5297add78f080fd4c7c0c7540416a58a
https://doi.org/10.1097/coc.0000000000000986
https://doi.org/10.1097/coc.0000000000000986
Publikováno v:
Chest. 161:e365-e369
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cd3b2baa7cc207d8c033a972208a13d
https://doi.org/10.1016/j.chest.2022.02.023
https://doi.org/10.1016/j.chest.2022.02.023
Publikováno v:
Cureus.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3aa879d72576c2ca68d91dffba95f9fb
https://doi.org/10.7759/cureus.33310
https://doi.org/10.7759/cureus.33310
Autor:
Ellery Altshuler, William King, Raymond Richhart, Keegan Hones, Akash Mathavan, Akshay Mathavan, Daniel F. Leach, Yasmeen Murtaza, Jimmy Lee, Denise Manfrini, Mohit Mathavan, Zahara Chowdhury, Sherise C. Rogers, Ibrahim Nassour, Brian Hemendra Ramnaraign, Ilyas Sahin, Aaron J Franke, Thomas J. George, Steven J. Hughes, Jesus C. Fabregas
Publikováno v:
Journal of Clinical Oncology. 40:e16306-e16306
e16306 Background: Duodenal adenocarcinoma (DA) is a rare malignancy with poor outcomes. Tumor markers are used to assess disease response and to monitor for recurrence. Specifically, CA-19-9 and CEA have been validated for use in pancreatic cancer a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61d0e787a937621fe94bafe4a03fb693
https://doi.org/10.1200/jco.2022.40.16_suppl.e16306
https://doi.org/10.1200/jco.2022.40.16_suppl.e16306